Applied Biosystems and SAIC-Frederick to Collaborate on NCI-Funded Genotyping Studies
News Apr 04, 2006
Applied Biosystems have announced at the 2006 Annual Meeting of the American Association for Cancer Research (AACR) that it has entered into a collaboration with the Core Genotyping Facility, SAIC-Frederick, Inc., a contractor for the National Cancer Institute (NCI), on a series of biomarker studies for cancer research.
The NCI-funded Core Genotyping Facility will use Applied Biosystems’ entire TaqMan® Drug Metabolism Genotyping Assay collection to examine genetic variations in the HapMap and SNP500Cancer samples in order to validate additional cancer biomarkers.
In support of the NCI, the Core Genotyping Facility is using more than 2,400 TaqMan Drug Metabolism Genotyping Assays to generate the genotypes for samples from the International HapMap Project and from NCI’s SNP500Cancer standard sample panel.
In addition, select assays with significant correlation from data analysis will be used to genotype individuals who participated in a pharmacogenetic study at the NCI evaluating treatment for Non-Hodgkin lymphoma.
“The objective of this study is to better understand the genetic differences associated with individual responses to cancer treatment,” said Dennis A. Gilbert, Ph.D., Chief Scientific Officer for Applied Biosystems.
“Because our TaqMan Drug Metabolism Genotyping Assays were developed using extensive computational analysis in combination with assay optimization and validation that identified novel and well-known gene variants, we believe they represent the most complete set of drug metabolism assays available to the scientific research community.
"We are pleased the SAIC-Frederick, under contract to the NCI, has selected them for this important project and are confident the assays will identify genetic variations important to various cancers for future pharmacogenetic studies and treatment guidelines.”
The Core Genotyping Facility will use samples from the HapMap project, SNP500Cancer, and Human Diversity Panel as controls to evaluate the genes included in the TaqMan Drug Metabolism Genotyping Assays.
Applied Biosystems and the Core Genotyping Facility will jointly analyze the resulting genotype data, and compare resulting data with previously published genotype and/or sequencing data for the same variants and individuals.
Final data meeting concordance/Mendelian transmission thresholds will be posted on the SNP500Cancer website (http://SNP500Cancer.nci.nih.gov) displaying the observed minor allele frequency, context sequences, and assay ordering information. The collaborators also plan to publish further findings.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.